Moringa possible treatment for peptic ulcers, scientists call for human clinical trials

Moringa is showing real promise as a natural ally against stomach ulcers. Experts, in a scientific review published in Frontiers in Pharmacology, say Moringa oleifera, popularly known as the “miracle tree,” has strong potential to protect and heal the stomach lining.

The study, titled “Preclinical Evidence of the Therapeutic Effect of Moringa oleifera in Peptic Ulcer Disease: A Systematic Review and Meta-analysis,” is the first comprehensive synthesis of experimental evidence evaluating the medicinal plant’s effectiveness against gastric ulcers.

A multidisciplinary team of researchers from the Biotechnology Advanced Research Centre (SHESTCO), the University of Medical Sciences, Ondo, and several collaborating institutions reviewed more than two decades of scientific research to determine whether Moringa could serve as a viable complementary therapy for one of the world’s most common gastrointestinal disorders.

The researchers analyzed 11 high-quality animal studies involving 268 laboratory animals and found that Moringa consistently reduced ulcer severity, protected the stomach lining, lowered gastric acid, boosted antioxidant activity and promoted tissue healing.

Peptic ulcer disease affects millions of people worldwide and remains a major public health concern, particularly in low- and middle-income countries where access to healthcare and modern medicines is often limited.

The condition develops when the protective lining of the stomach or the upper part of the small intestine is damaged, resulting in painful sores that can cause abdominal pain, nausea, bleeding and, in severe cases, life-threatening complications.

Although conventional medications such as proton pump inhibitors (PPIs) and H2 receptor antagonists remain the standard treatment for ulcers, long-term use is often associated with high costs, recurrent symptoms, adverse side effects and growing concerns over prolonged therapy.

These challenges have prompted scientists to explore affordable plant-based alternatives with proven therapeutic value. For generations, communities across Africa and Asia have relied on Moringa to treat digestive disorders, making it an attractive candidate for scientific investigation.

For the review, the researchers evaluated studies involving different parts of the Moringa plant—including its leaves, seeds, flowers, fruits and root bark—using various extraction methods and experimental ulcer models before conducting a meta-analysis to determine the plant’s overall therapeutic effect.

The findings showed that Moringa performed remarkably well across several ulcer models induced by alcohol, stress, aspirin, ibuprofen and other non-steroidal anti-inflammatory drugs. In some studies, the plant achieved up to 95 per cent ulcer protection, with effects comparable to commonly prescribed anti-ulcer drugs such as cimetidine.

According to the researchers, Moringa’s impressive therapeutic effects are driven by a rich combination of naturally occurring bioactive compounds that work through several protective mechanisms simultaneously.

These compounds help reduce inflammation, neutralize harmful free radicals, stabilize gastric cells, suppress excessive acid secretion, improve blood flow to damaged tissues and stimulate mucus production, which protects the stomach lining from further injury.

The review also found evidence suggesting that Moringa possesses antimicrobial activity against Helicobacter pylori, the bacterium responsible for many peptic ulcers worldwide. Researchers believe the plant’s various compounds work synergistically, explaining its broad range of protective effects.

Importantly, none of the studies reported significant safety concerns, even at relatively high doses, making Moringa a promising candidate for future therapies.

The review further revealed that the plant’s effectiveness varied depending on the part used and the extraction method employed. Methanol extracts generally demonstrated stronger ulcer-healing effects than aqueous extracts.

Leaf extracts were the most extensively studied and consistently produced beneficial outcomes, while root bark extracts also showed remarkable activity, achieving ulcer inhibition rates of up to 86 per cent in some experiments. Seed extracts also demonstrated beneficial effects but were generally less potent than leaf or root preparations.

The researchers also compared Moringa’s performance with commonly prescribed anti-ulcer medications, including omeprazole, cimetidine, ranitidine and famotidine.

Although several studies found that high-dose Moringa extracts produced effects comparable to cimetidine and some other conventional therapies, the overall meta-analysis showed that the plant did not consistently outperform established medications. In particular, omeprazole remained significantly more effective than low-dose Moringa in reducing ulcer severity.

Based on these findings, the researchers concluded that Moringa should currently be regarded as a potential adjunct therapy that could complement conventional treatment rather than replace it.

One of the review’s most encouraging findings was the plant’s apparent safety. Across all the studies reviewed, researchers reported no significant adverse effects, even when laboratory animals received relatively high doses of Moringa extracts. Experimental doses of up to 1,500 milligrams per kilogram of body weight were well tolerated without observable toxicity.

However, the review also noted that none of the studies examined long-term safety, chronic toxicity or potential interactions between Moringa and prescription medications, underscoring the need for further research.

The researchers also cautioned against interpreting the findings as proof that Moringa can treat peptic ulcers in humans, noting that all the available evidence comes from laboratory animal studies rather than clinical trials.

Consequently, the review urges governments, research institutions and healthcare policymakers to invest in well-designed human clinical trials.

Future research, the authors said, should focus on developing standardized extraction methods, determining optimal dosages, evaluating long-term safety, investigating herb-drug interactions and confirming the plant’s therapeutic effectiveness in patients with peptic ulcer disease.

ALSO READ: JAMB registrar resolves over 5,000 pending complaints in five days

They believe such studies could have significant public health implications, particularly in developing countries where Moringa is widely available and conventional ulcer medications remain unaffordable for many patients.

If future clinical trials confirm the promising laboratory findings, Moringa could emerge as an inexpensive, locally available complementary therapy capable of reducing the burden of peptic ulcer disease, especially in resource-limited settings.

Given Moringa’s affordability, availability, and widespread use in traditional medicine across Africa and Asia, researchers believe it could one day become a valuable complementary treatment—especially in low-resource settings where access to conventional medicines remains limited.